Who Generates Higher Gross Profit? Biogen Inc. or Incyte Corporation

Biogen leads, but Incyte's growth is impressive!

__timestampBiogen Inc.Incyte Corporation
Wednesday, January 1, 20148532288000508491000
Thursday, January 1, 20159523400000726779000
Friday, January 1, 201699701000001047532000
Sunday, January 1, 2017106439000001456737000
Monday, January 1, 2018116366000001787760000
Tuesday, January 1, 2019124225000002044510000
Wednesday, January 1, 2020116394000002535374000
Friday, January 1, 202188720000002835276000
Saturday, January 1, 202278951000003187638000
Sunday, January 1, 202373022000003440649000
Monday, January 1, 202496759000003929149000
ngram

Biogen Inc. vs. Incyte Corporation: A Decade of Gross Profit Trends

In the competitive landscape of biotechnology, understanding which companies lead in profitability is crucial. Over the past decade, Biogen Inc. has consistently outperformed Incyte Corporation in terms of gross profit. From 2014 to 2023, Biogen's gross profit peaked in 2019, reaching nearly 12.4 billion, while Incyte's highest was in 2023, with approximately 3.4 billion. Despite Biogen's dominance, Incyte has shown remarkable growth, with its gross profit increasing by over 575% from 2014 to 2023. This trend highlights Incyte's rapid expansion and potential to challenge industry giants. As the biotech sector evolves, these financial insights provide a glimpse into the strategic maneuvers of these companies, offering investors and analysts a deeper understanding of their market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025